GLP-1 Coverage: Employers Balance Access, Cost, and Control
GLP-1 medications have quickly become a major topic in employee benefits strategy. These drugs, known as GLP-1 agonists, are widely used to treat type 2 diabetes and, when combined with other care approaches, to support weight loss. Their effectiveness has fueled strong employee interest, but their high and recurring cost is forcing employers to make difficult decisions about whether and how to include them in health plan coverage.
For business leaders, the issue is no longer simply whether GLP-1 medications work. The challenge is how to balance employee access, clinical appropriateness, and long-term healthcare affordability.
Coverage Is Common, but Commitment Is Uncertain
Nearly 70 percent of employers currently include GLP-1 medications for weight management in their insurance coverage. Yet that coverage is far from guaranteed in the years ahead. Just under three-quarters of employers that currently cover the drugs expect to continue doing so in 2027, while 10 percent say they definitely will not continue coverage.
Employers that do not currently cover GLP-1 medications are also generally not planning to add them. The reason is clear: approximately 80 percent of companies that offer GLP-1 coverage say the medications are increasing prescription-drug spending.
This creates a growing tension for employers. Workers may view GLP-1 access as an important health benefit, particularly as awareness of the medications expands. At the same time, open eligibility is difficult for many plans to sustain, even when the potential health benefits are evident.
Employers Are Building Guardrails Around Access
Rather than offering unrestricted coverage, many employers are introducing clinical and financial safeguards intended to ensure GLP-1 medications are used appropriately. Common approaches include:
Limiting eligibility to FDA-approved indications, such as medically supported type 2 diabetes or obesity above a specified body mass index threshold.
Using prior authorization or step therapy to require employees to try lower-cost alternatives before GLP-1 medications are approved, unless those alternatives are shown to be ineffective.
Working with direct-to-employer prescription-drug platforms that can develop more tailored GLP-1 programs and care pathways.
Using FSAs or HRAs to help offset employees’ out-of-pocket costs when coverage is limited or cost sharing is significant.
These guardrails can support more clinically appropriate use and help employers communicate a consistent benefits policy. However, many employers report that utilization controls alone have not meaningfully reduced the overall cost impact. The medications’ price, combined with the possibility of ongoing or long-term use, means that even tightly managed programs can create material budget pressure.
Affordability Is a System-Wide Concern
The GLP-1 issue is part of a broader healthcare affordability challenge. Mercer warned of a growing “healthcare affordability crunch” driven by rising costs, with GLP-1 medications representing a meaningful component of that concern for many employer-sponsored plans.
The cost challenge extends beyond employers. Earlier this year, an Employee Benefit Research Institute survey found that more than one-third of GLP-1 users had discontinued the medication, with cost cited as the most common reason. This highlights a key concern for benefits leaders: a plan design that makes treatment technically available may still fail to support meaningful continuity of care if the employee’s out-of-pocket expense remains too high.
Medicare beneficiaries received some additional support effective July 1, becoming eligible for a $50-per-month subsidy toward GLP-1 drugs. While this may help some individuals manage the expense, it does not eliminate the larger affordability questions facing employers and commercial health plans.
A Strategic Benefits Decision, Not a One-Time Coverage Choice
Employers considering GLP-1 coverage should treat the decision as part of a larger benefits and workforce-health strategy. The most effective approach is likely to combine clearly defined clinical eligibility, thoughtful pharmacy-benefit management, employee education, and regular monitoring of utilization and cost trends.
Business leaders should also consider what success looks like. Is the goal to support treatment for specific medical conditions, improve access to weight-management resources, reduce downstream health risks, strengthen recruitment and retention, or some combination of these outcomes? Defining that objective can help employers choose a plan design that aligns with both workforce needs and financial realities.
GLP-1 medications are likely to remain a prominent and evolving benefits issue. Employers that establish clear policies now, communicate them transparently, and review their approach as costs and clinical guidance change will be better positioned to manage both employee expectations and long-term plan affordability.